Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:

3 patent-pending new drug families drawing on novel chemical structures;

75 compounds synthesized with preclinical data demonstrating promising results; and

Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Stock Quote

Press Releases & News

Mindset Pharma Invited to Present at Canaccord Genuity 41st Annual Growth Conference

May 5, 2021

Read More

Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds

April 29, 2021

Read More

Mindset Pharma Engages KCSA Strategic Communications to Provide Investor Relations Services

April 28, 2021

Read More